1.Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383:2168–79.
2.Chun YS, Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24:1073274817729241.
3.Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM et al. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016; 122:3657–66.
4.Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM et al. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012; 147:1107–13.
5.Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008; 13:415–23.
6.Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010; 28:3531–40.
7.Weber SM, Ribero D, O’Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015; 17:669–80.
8.Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018; 37:555–65.
9.LeRoy G, Orphanides G, Lane WS, Reinberg D. Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science. 1998; 282:1900–4.
10.Wang Y, Li H, Lu H, Qin Y. Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR–19b–3p/HOXA9 axis. Onco Targets Ther. 2019; 12:7055–65.
11.Tian JDC, Liang L. Involvement of circular RNA SMARCA5/microRNA–620 axis in the regulation of cervical cancer cell proliferation, invasion and migration. Eur Rev Med Pharmacol Sci. 2018; 22:8589–98.
12.Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018; 68:1214–27.
13.Cai J, Chen Z, Zuo X. circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer. Dis Markers. 2019; 2019:2473652.
14.Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta. 2019; 492:37–44.
15.Lendvai G, Szekerczes T, Illyes I, Dora R, Kontsek E, Gogl A et al. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis. Pathol Oncol Res. 2018.
16.Wang M, Gao Y, Feng H, Warner E, An M, Jia J et al. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Cancer Med. 2018; 7:646–54.
17.NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers (Version 2.2014).
18.Xu Y, Yao Y, Liu Y, Wang Z, Hu Z, Su Z et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR–1238 and miR–1299 in cholangiocarcinoma. Aging (Albany NY). 2019; 11:1907–17.
19.Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol Commun. 2018; 2:254–69.
20.Barbagallo D, Caponnetto A, Cirnigliaro M, Brex D, Barbagallo C, D’Angeli F et al. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018; 19.
21.Aydin OZ, Vermeulen W, Lans H. ISWI chromatin remodeling complexes in the DNA damage response. Cell Cycle. 2014; 13:3016–25.
22.Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364–78.